<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03671889</url>
  </required_header>
  <id_info>
    <org_study_id>AL002</org_study_id>
    <nct_id>NCT03671889</nct_id>
  </id_info>
  <brief_title>ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease</brief_title>
  <official_title>Assessment of Safety and Efficacy of ExAblate Blood-Brain Barrier Disruption for the Treatment of Patients With Probable Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InSightec</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InSightec</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of the ExAblate Model 4000
      Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable
      Alzheimer's Disease (AD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, single-arm study to evaluate the safety and efficacy of
      BBB disruption using the ExAblate Model 4000 Type 2.0 (220 kHz) system. Patients with
      diagnosis of Probable Alzheimer's Disease may qualify for a clinical trial to have three
      serial ExAblate BBB disruption procedures in specific areas in the brain. This study will be
      conducted at up to 4 sites in the United States and will enroll up to 20 patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2018</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Subjects who meet study eligibility will undergo treatment procedures in groups by staged volumes.</intervention_model_description>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Device and procedure related adverse events</measure>
    <time_frame>5 years</time_frame>
    <description>Rate of adverse events following each treatment through end of study</description>
  </primary_outcome>
  <other_outcome>
    <measure>BBB Disruption and Closure</measure>
    <time_frame>Immediately after the end of each ExAblate treatment and 24 hours post treatment</time_frame>
    <description>MR images post-procedure to verify that the BBB was disrupted and subsequently closed within 24 hours.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Blood Brain Barrier (BBB) Disruption</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ExAblate Model 4000 Type 2.0 System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Blood Brain Barrier (BBB) Disruption</intervention_name>
    <description>Focal Ultrasound (FUS) involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct targets to induce BBB disruption.</description>
    <arm_group_label>Blood Brain Barrier (BBB) Disruption</arm_group_label>
    <other_name>ExAblate Neuro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or Female between 50-85 years of age

          2. Probable Alzheimer's Disease (AD)

          3. If taking concurrent Alzheimer's medication, has been on the medication for at least 2
             months with a stable dose for at least 3 months

          4. Able to communicate sensations during the ExAblate MRgFUS procedure

          5. Ambulatory

        Exclusion Criteria:

          1. MRI Findings

          2. Presence of unknown or MR unsafe devices anywhere in the body

          3. Significant cardiac disease or unstable hemodynamic status

          4. Relative contraindications to ultrasound contrast agent or PET amyloid tracer

          5. History of a bleeding disorder

          6. History of liver disease

          7. Known cerebral or systemic vasculopathy

          8. Significant depression and at potential risk of suicide

          9. Any contraindications to MRI scanning

         10. Any contraindication to lumbar puncture for collection of cerebral spinal fluid

         11. Untreated, uncontrolled sleep apnea

         12. History of seizure disorder or epilepsy

         13. Severely Impaired renal function

         14. Currently in a clinical trial involving an investigational product or non-approved use
             of a drug or device or in any other type of medical research

         15. Chronic pulmonary disorders

         16. Positive human immunodeficiency virus (HIV)

         17. Known apolipoprotein E allele (ApoE4) homozygosity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Desiree Dorrough</last_name>
    <phone>469-607-0486</phone>
    <email>desireed@insightec.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marissa Michael</last_name>
      <phone>212-746-7373</phone>
      <email>mam4001@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Kaplitt, M.D., PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University -Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Woodburn</last_name>
      <phone>614-366-7822</phone>
      <email>Erin.Woodburn@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Vibhor Krishna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University Rockefeller Neuroscience Center</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Harring</last_name>
      <phone>304-293-9638</phone>
      <email>barbara.harring@hsc.wvu.edu</email>
    </contact>
    <investigator>
      <last_name>Ali R Rezai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 3, 2018</study_first_submitted>
  <study_first_submitted_qc>September 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2018</study_first_posted>
  <last_update_submitted>April 24, 2020</last_update_submitted>
  <last_update_submitted_qc>April 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer Disease</keyword>
  <keyword>Alzheimer Syndrome</keyword>
  <keyword>Magnetic Resonance guided Focal Ultrasound (MRgFUS)</keyword>
  <keyword>Blood-Brain Barrier</keyword>
  <keyword>ExAblate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

